Hemophilia B — Deal Benchmarks & Valuation
Market Analysis
Hemophilia B is one of the most actively transacted indications in rare disease licensing. Phase 2 deals for hemophilia b carry a median total deal value of $1.8B, with upfront payments ranging from $158M to $496M. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones.
Milestone structures for hemophilia b deals allocate $325M to development milestones, $369M to regulatory milestones, and $782M to commercial milestones. Royalty rates range from 8.1% to 16.3% at the base tier, with tiered escalation reaching 12.1%-20.3% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for hemophilia b licensing?
What royalty rates are standard for hemophilia b deals?
How are hemophilia b deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.